drugset / Trial / NCT05326087

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

NCT05326087

Phase 3 Not yet recruiting 204 enrolled ShangHai Ji Ai Genetics & IVF Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. PPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger. The primary outcome is the euploidy rate of blastocysts.

Timeline

Start
2026-06-01
Primary completion
2027-12-01
Completion
2028-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cetrorelix Other / unclassified 0.25 mg Subcutaneous
Subject medroxyprogesterone acetate Other / unclassified 10 mg Oral